D3 Bio

D3 Bio is a clinical-stage biotechnology company based in Wuxi, China, founded in 2020.

The company focuses on discovering, developing, and registering innovative medicines, primarily in oncology and immunology. D3 Bio aims to address unmet patient needs by guiding research toward precision therapies, utilizing proprietary clinical insights and biomarker strategies to target specific mutations and immune pathways. The lead asset, elisrasib (D3S-001), is a KRAS G12C inhibitor that is advancing to global Phase III pivotal trials for treating KRAS G12C-mutant cancers. D3 Bio has a robust pipeline and owns global rights for all its programs. The company is committed to enrolling patients in clinical trials to expedite regulatory approvals and offers expanded access programs for investigational drugs in serious conditions. D3 Bio has successfully raised significant funding to support its initiatives, totaling $240 million, with recent investments aimed at advancing its lead programs.